Form 4: Acelyrin Director Lynn A. Tetrault Reports Stock Option Grant
SEC Form 4 Filing
Director Lynn A. Tetrault reports the acquisition of stock options in Acelyrin, Inc.
Summary
- On June 7, 2024, Lynn A. Tetrault, a director of Acelyrin, Inc., was granted stock options to purchase 43,680 shares of common stock.
- The exercise price of the options is $4.46 per share.
- The options vest on the earlier of June 7, 2025, or the day before the next annual meeting of stockholders following the grant date, contingent upon continued service as a director.
Sentiment
Score: 6
Explanation: The document is a standard regulatory filing related to stock option grants, which is generally neutral in sentiment. It reflects standard compensation practices.
Positives
- The grant of stock options aligns the director's interests with those of the shareholders, incentivizing her to work towards increasing the company's value.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.
Industry Context
Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/07/2024 | Date of the stock option grant. |
| 06/07/2025 | First possible vesting date for the stock options. |
| 06/06/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.